Skip to main content
SPT logo

SPT — Investor Relations & Filings

Ticker · 1789 ISIN · TW0001789006 TW Manufacturing
Open in API
Filings indexed 2,236 across all filing types
Latest filing 2023-06-16 AGM Information
Country TW Taiwan
Listing TW 1789

About SPT

https://www.scinopharm.com/tw

ScinoPharm Taiwan, Ltd. is a global provider of high-quality Active Pharmaceutical Ingredients (APIs) and comprehensive Contract Development and Manufacturing Organization (CDMO) services. The company specializes in process research, development, and cGMP production, maintaining a leadership position in oncology APIs. Its portfolio covers therapeutic areas including cancer, hematology, metabolic disorders, and central nervous system diseases. ScinoPharm offers one-stop solutions encompassing peptide synthesis, API process development, and the manufacturing of sterile injectables and complex generics. The company is distinguished by its expertise in high-barrier pharmaceutical technologies and adherence to stringent international regulatory standards, such as the U.S. FDA. Serving both generic and innovative drug sectors, it leverages advanced R&D and integrated manufacturing to support global healthcare markets.

Recent filings

Filing Released Lang Actions
112年年報及股東會資料 — 2023_1789_20230529FE1.pdf
AGM Information Classification · 95% confidence The document is a notice for the 2023 Annual General Shareholders' Meeting of ScinoPharm Taiwan, Ltd. It includes the meeting agenda, date, location, and procedural details such as voting and proxy information. It mentions reports and ratifications to be discussed at the meeting but does not contain the full reports or financial statements themselves. The document length is 3311 characters, which is relatively short and consistent with a meeting notice rather than a full report. The content aligns with an announcement of an AGM meeting and its agenda rather than the actual AGM materials or minutes. Therefore, the document fits the category of AGM Information (AGM-R).
2023-06-16 Chinese
112年年報及股東會資料 — 2023_1789_20230529F02.pdf
Annual Report Classification · 100% confidence The document is a detailed shareholder meeting manual for Taiwan Shenlong Co., Ltd. for the year 112 (2023), including the agenda, proposals, and attachments such as the annual business report, audit committee report, amendments to board meeting rules, individual and consolidated financial statements with auditor's reports, profit distribution, and election of independent directors. The document contains extensive financial data, auditor's opinions, and management reports for the fiscal year 111 (2022). It is clearly the full annual report and related materials presented at the Annual General Meeting. The presence of the full financial statements and auditor's report confirms this is the Annual Report itself, not just an announcement or summary. Therefore, the appropriate classification is Annual Report (10-K). FY 2022
2023-06-16 Chinese
112年年報及股東會資料 — 2023_1789_20230529F01.pdf
AGM Information Classification · 100% confidence The document is a detailed notice for a shareholders' meeting (股東常會) of Taiwan Shenlong Co., Ltd. It includes information about the meeting date, agenda items such as approval of the 111th fiscal year business report and financial statements, dividend distribution, amendments to company articles, election of independent directors, and other shareholder meeting procedural details. It also contains proxy forms and instructions for shareholders to participate and vote. The content is consistent with materials typically distributed for an Annual General Meeting (AGM) to inform shareholders and facilitate their participation. There is no actual financial data or full report included, but rather the meeting notice and related proxy documents. Therefore, this document fits the category of AGM Information (AGM-R).
2023-06-16 Chinese
112年06月法人說明會簡報 — 178920230608E001.pdf
Investor Presentation Classification · 95% confidence The document is titled 'ScinoPharm Investor Conference 2023 06 08' and contains detailed company overview, business updates, financial performance data including consolidated income statement, balance sheet, and cash flow statement for 1Q 2023, as well as sales distribution and market information. It includes forward-looking statements and detailed financial and operational data, typical of an investor presentation. There is no indication that this is a full annual or quarterly report filing, nor is it a transcript or regulatory filing. The content is consistent with a detailed presentation aimed at investors, covering strategy, financials, and market position. The document length (13,858 characters) supports it being a full presentation rather than a brief announcement or certification. Therefore, the most appropriate classification is Investor Presentation (IP).
2023-06-08 Chinese
112年06月法人說明會簡報 — 178920230608M001.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed presentation from ScinoPharm Taiwan, Ltd. dated June 8, 2023, containing company overview, business status, financial performance including consolidated income statement, balance sheet, and cash flow statement for Q1 2023, as well as product pipeline and market information. It includes forward-looking statements, detailed financial data, and operational updates. The presence of financial statements and comprehensive business and financial information indicates this is a quarterly or interim report rather than a brief earnings release or an announcement. The length (over 10,000 characters) and detailed financial tables confirm it is a substantive financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2023
2023-06-08 Chinese
112年06月法人說明會簡報
Investor Presentation Classification · 95% confidence The document is a listing from a public information observation station showing details about a company's investor conference call or presentation. It includes the company code, name, date and time of the investor presentation, location (online meeting), summary of the presentation content, links to PDF files of the presentation materials, and video links. The content is focused on a '法人說明會' which translates to 'investor presentation' or 'analyst meeting'. There is no detailed financial report or earnings data included, only references to presentation materials and a video link. The document length is short (874 characters) and it is clearly an announcement or summary of an investor presentation event rather than a full report or transcript. Therefore, the most appropriate classification is Investor Presentation (IP).
2023-06-08 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.